IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Assessing the Effects of Nitrosamines in Pharmaceutical Products and Implementing Effective Control Strategies

Garimi Tirumala Jyothesh Kumar*, B.S.A. Andrews[1], V D N Kumar Abbaraju[2]
[1,2,*]Department of Chemistry, GSS, GITAM University, Visakhapatnam – INDIA – AP – 530045.
[1]Department of Environmental Sciences, GSS, GITAM University, Visakhapatnam – INDIA – AP – 530045.

Abstract:
Nitrosamines, a class of organic compounds, have recently garnered considerable attention within the pharmaceutical industry due to their potential carcinogenic properties. This research paper delves into the intricate web of nitrosamines, exploring their formation mechanisms, their repercussions on pharmaceutical products, and the multifaceted strategies employed to maintain their presence within acceptable limits. Nitrosamines can inadvertently emerge as impurities in diverse drug formulations, thereby posing significant challenges concerning patient safety and adherence to stringent regulatory compliance. To effectively mitigate these risks, pharmaceutical manufacturers must adhere to a rigorous array of control measures, encompassing comprehensive risk assessments, analytical testing protocols, and meticulous process optimization strategies. This paper offers an in-depth analysis of nitrosamines, scrutinizing their intricate formation mechanisms, their implications for pharmaceutical products, and the control strategies imperative to ensure the safety and efficacy of medications.

Key Word: Pharmaceutical Industry, Nitrosamine, Risk assessment, Control Strategy

Introduction:
Pharmaceutical products have evolved into an indispensable element of modern healthcare, fulfilling a pivotal role in the treatment and management of a wide range [1]of medical conditions. Their significance cannot be overstated, as they are responsible for improving the quality of life and extending the lifespans of millions of individuals worldwide. However, alongside their unquestionable benefits, the pharmaceutical industry is faced with an ever-present challenge - the need to ensure the safety and efficacy of the products [2] it produces. This imperative forms the bedrock of pharmaceutical regulation, and any compromise in this regard can have severe consequences for public health.

In recent years, a new threat has emerged, casting a shadow over the pharmaceutical industry and the health of those who rely on its products. Nitrosamines, a class of organic compounds featuring a distinctive nitroso group (R-NO), have assumed paramount importance within the pharmaceutical realm. The reason for this heightened concern lies in the potential carcinogenicity associated with these compounds. Carcinogens are agents that can cause cancer, and as such, their presence in pharmaceutical products is a matter of utmost alarm.

This research paper endeavors to meticulously dissect the intricate formation mechanisms of nitrosamines, scrutinize their potential repercussions on pharmaceutical products, and explore the nuanced strategies that have been employed to control their presence within established limits. By doing so, it seeks to shed light on a critical issue that affects not only the pharmaceutical industry but also the well-being of patients who rely on these medications.

The paper will begin by delving into the origins and chemical properties of nitrosamines, outlining the pathways through which they can be formed in pharmaceutical products. It will also explore the potential risks that [3] nitrosamines pose to human health and the regulatory framework in place to address this threat. In addition, it will discuss the methods and technologies that pharmaceutical companies employ to detect, mitigate, and prevent nitrosamine contamination. This research paper ultimately aims to contribute to a deeper understanding of the challenges and solutions [4] associated with the presence of nitrosamines in pharmaceuticals, with the overarching goal of ensuring the continued safety and efficacy of these vital healthcare products.

2 Nitrosamines: An Overview:

2.1. Chemical Structure and Classification:

Nitrosamines are a class of chemical compounds that are distinguished by a specific chemical structure characterized by the presence of the nitroso group (NO) bonded to an amine or amide compound. The nitroso group consists of a nitrogen atom (N) and an oxygen atom (O) and is attached to a nitrogen atom (N) in an amine or amide molecule.

This chemical class, nitrosamines, can be further classified into various subgroups based on their structural diversity. Some notable examples of nitrosamines include:

N-nitrosodimethylamine (NDMA): NDMA has a dimethylamine group as part of its structure, and it is a well-known environmental contaminant and a potential carcinogen. NDMA is often associated with the degradation of various chemicals, including some pharmaceuticals and pesticides. Fig 1



Fig 1 N-nitrosodimethylamine (NDMA)

N-nitrosodiethylamine (NDEA): NDEA features a diethylamine group in its structure. Like NDMA, NDEA is considered a potential carcinogen and can be found in certain environmental and industrial settings. Fig 2



Fig 2 N-nitrosodiethylamine (NDEA)

N-nitrosomethylaminobutyric acid (NMBA): NMBA includes an aminobutyric acid group in its structure. It is another nitrosamine compound that is associated with potential carcinogenicity and may be found in various chemical processes. Fig 3



Fig 3: N-nitrosomethylaminobutyric acid (NMBA)

N-nitrosopiperidine (NPIP): NPIP contains a piperidine group as part of its structure. It is also classified as a nitrosamine and is known to possess carcinogenic properties. Fig 4



Fig 4: N-nitrosopiperidine (NPIP)

These nitrosamines are of concern because some of them are classified as probable or possible human carcinogens. They can be found in various products, including some pharmaceuticals, processed foods, tobacco smoke, and industrial chemicals. Regulatory agencies and health organizations closely monitor and regulate the presence of nitrosamines in consumer products to mitigate potential health risks associated with their exposure.

2.2. Formation Mechanisms:

Nitrosamines are a group of organic compounds that contain the nitroso functional group (NO). Some nitrosamines have been identified as potentially carcinogenic to humans, and their presence in pharmaceutical products is a matter of great concern. These compounds can form through complex chemical reactions, and their formation in pharmaceuticals can occur via several intricate mechanisms. Here's a more detailed explanation:

Nitrosating Agents: Nitrosating agents are chemical substances that contain a nitroso group or can generate nitrosating species. These agents can exist in trace amounts within the raw materials used in pharmaceutical manufacturing or can be generated during various stages of the drug production process.

Secondary Amines and Amides: Secondary amines (amines with two alkyl or aryl groups bonded to [5] the nitrogen atom) and amides (compounds derived from amines) are often present in pharmaceutical compounds. These compounds can serve as precursors for nitrosamine formation.

Reaction Pathways: One common pathway for nitrosamine formation involves the reaction between nitrosating agents and secondary amines or amides. In this reaction, the nitrosating agent can donate a nitroso group (NO) to the secondary amine or amide, leading to the creation of a nitrosamine compound.

Example with NDMA: N-Nitrosodimethylamine (NDMA) is a well-known nitrosamine. It can inadvertently form when dimethylamine, a secondary amine, reacts with nitrite or other nitrosating agents during the synthesis of certain medications. This reaction is just one example of how nitrosamines can be generated within pharmaceutical products. Fig 5



Fig 5: Formation of NDMA

Control and Prevention: Given the potential health risks associated with nitrosamines, pharmaceutical companies and regulatory authorities have implemented strict controls and guidelines to prevent their formation. This includes rigorous testing of raw materials, the use of analytical methods to detect nitrosamines, and the development of manufacturing processes that minimize the potential for nitrosamine formation.

The formation of nitrosamines in pharmaceutical products is a complex process that involves the interaction of nitrosating agents with secondary amines or amides. Understanding and controlling this process is crucial to ensure the safety and quality of pharmaceutical drugs.

3 Impacts of Nitrosamines in Pharmaceutical Products

3.1. Carcinogenicity:

The presence of numerous nitrosamines, such as NDMA and NDEA, has become a matter of paramount concern within the pharmaceutical and healthcare communities. These compounds have received a

classification as "probable human carcinogens" by influential global health organizations, including the International Agency for Research on Cancer (IARC) [6] . This classification indicates a substantial level of apprehension regarding nitrosamines. What amplifies this concern is the discovery of these nitrosamines as impurities in pharmaceutical products. Pharmaceuticals are engineered to enhance and safeguard human health, and the detection of potential carcinogens like nitrosamines within them raises significant safety issues for patients. Prolonged exposure to these impurities in medications could potentially heighten the risk of cancer for individuals, which is particularly alarming since patients often rely on these drugs for extended periods. As a result, it is imperative for pharmaceutical manufacturers and health regulatory authorities to rigorously monitor and control the presence of nitrosamine impurities in medications to ensure the well-being and safety of patients.

Addressing the issue of nitrosamines in pharmaceutical products requires a multi-pronged approach. These chemical compounds, including NDMA and NDEA, have been identified as having a concerning potential to cause cancer in humans, a classification made by reputable organizations like the International Agency for Research on Cancer (IARC). The real cause for alarm lies in their presence as contaminants in medicinal products, where patient safety is of paramount importance. Given that patients often take these medications for extended periods, the cumulative exposure to these carcinogenic impurities can pose a significant health risk. This necessitates stringent quality control measures in pharmaceutical manufacturing to detect and eliminate nitrosamine impurities and stringent regulatory oversight to ensure that the medications people rely on are free from such potentially harmful substances. Safeguarding the health of patients and addressing the safety concerns surrounding nitrosamine impurities is an ongoing challenge that requires collaboration between pharmaceutical companies, regulatory agencies, and the scientific community.

3.2. Regulatory Compliance:

Regulatory agencies like the U.S. Food and Drug Administration (FDA) [7], the European Medicines Agency (EMA), and their counterparts in other countries play a crucial role in ensuring the safety and efficacy [8] of pharmaceutical products. They establish and enforce regulations and standards to protect public health and maintain the quality of [9] pharmaceuticals. Nitrosamine impurities have received significant attention due to their potential health risks, which has led to the establishment of stringent limits and guidelines by these agencies.

U.S. Food and Drug Administration (FDA): The FDA [10] is the regulatory authority responsible for overseeing the safety and effectiveness of pharmaceuticals in the United States. The FDA has set strict limits for nitrosamine impurities in pharmaceutical products. For example, it has established acceptable daily intake (ADI) levels for nitrosamines at exceptionally low levels, typically in the range of nanograms per day. The FDA conducts inspections, reviews data, and collaborates with manufacturers to ensure compliance with these limits. Failure to adhere to these limits can result in [11] regulatory actions, product recalls, and legal consequences.

European Medicines Agency (EMA): The EMA is the regulatory agency responsible for overseeing pharmaceuticals in the European Union (EU). It has also established stringent limits for nitrosamine impurities in pharmaceutical products. The EMA works in conjunction with national agencies to ensure that pharmaceutical companies comply with these limits. Non-compliance can lead to the suspension or withdrawal of marketing authorizations, product recalls, and other regulatory actions.

Global Counterparts: Regulatory agencies in other countries, such as Health Canada, the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, and the Therapeutic Goods Administration (TGA) in Australia, have also instituted similar regulations and guidelines regarding nitrosamine impurities. These agencies work to protect public health within their respective regions and ensure that pharmaceutical companies adhere to stringent standards.

The consequences of failing to adhere to the established limits for nitrosamine impurities within pharmaceuticals can be severe. They may include:

Product Recalls: Regulatory agencies can require pharmaceutical companies to recall products that exceed the acceptable limits for nitrosamine impurities. This can result in financial losses and reputational damage[12].

Regulatory Actions: Regulatory agencies have the authority to take various actions against non-compliant companies, including issuing warning letters, fines, suspension or revocation of marketing authorizations, and legal actions.

Reputational Damage: Beyond regulatory actions, violations of nitrosamine limits can lead to a loss of trust and reputation damage for pharmaceutical companies. This can have long-lasting effects on their business and public perception.

Regulatory agencies like the FDA, EMA, and their global counterparts play a critical role in ensuring pharmaceutical safety by setting and enforcing strict limits for nitrosamine impurities. Compliance with these limits is essential to avoid product recalls, regulatory actions, and reputational harm, while also safeguarding public health.

3.3. Patient Confidence:

The detection of nitrosamines in pharmaceutical products has the potential to significantly erode patient confidence in the safety and effectiveness of their prescribed medications, creating ripple effects throughout the healthcare ecosystem. Nitrosamines, recognized carcinogens, raise substantial concerns about patient safety. Prominent cases like the recall of ranitidine products due to NDMA contamination have brought this issue to the forefront, prompting patients to question the pharmaceutical industry's commitment to their well-being. This decline in trust has broader implications for patients' treatment adherence and casts a shadow on pharmaceutical companies and regulatory agencies alike.

Mitigating this challenge necessitates a comprehensive strategy. The pharmaceutical industry must prioritize rigorous quality control measures, enhanced testing protocols, and advanced manufacturing processes to prevent nitrosamine formation. Transparent and effective communication is paramount, ensuring that patients are promptly and comprehensively informed about potential risks and the proactive measures being taken to rectify them. Engaging healthcare providers in this process is essential for sustaining the doctor-patient relationship. The restoration and perpetuation of patient trust in the safety and efficacy of prescribed medications is pivotal for both individual well-being and the reputation of the pharmaceutical industry.

4 Control Strategies for Nitrosamines in Pharmaceutical Products:

4.1. Risk Assessment:

In GMP (Good Manufacturing Practices), risk assessment is a crucial aspect for pharmaceutical manufacturers to ensure the safety and quality of their products. Here's an elaboration of the provided text on how pharmaceutical manufacturers should conduct risk assessments related to nitrosamine formation:

Comprehensive Approach: Pharmaceutical manufacturers need to adopt a comprehensive approach when conducting risk assessments. This means they must leave no stone unturned when it comes to identifying potential sources [13] of nitrosamine formation. The process involves a thorough and systematic investigation of all relevant factors.

Identification of Nitrosamine Precursors: One of the key elements in risk assessment is identifying nitrosamine precursors. Nitrosamines are potentially carcinogenic compounds that can form during drug manufacturing processes. These precursors can be found in raw materials, solvents, or even within the production equipment. The risk assessment process involves pinpointing these precursors.

Raw Materials Examination: Raw materials used in drug manufacturing must be carefully scrutinized for the presence of nitrosamine precursors. This examination ensures that the starting materials are free from contamination or impurities that could lead to nitrosamine formation during the synthesis process.

Solvents Analysis: Solvents used in drug formulation should also be analyzed for nitrosamine precursors. Even trace amounts of these precursors in solvents can lead to the unintentional formation of nitrosamines during the drug production process.

Production Equipment Inspection: The risk assessment includes a thorough examination of production equipment. This is done to identify any potential areas or components that may be susceptible to nitrosamine contamination. Proper cleaning and maintenance procedures should be in place to prevent such contamination.

Synthesis Pathway Evaluation: The synthesis pathway for a drug formulation is a critical focus of the risk assessment. Manufacturers must carefully evaluate each step in the manufacturing process to determine if any specific conditions or reactions could facilitate nitrosamine formation. Adjustments or preventive measures may be necessary to minimize this risk.

Probability and Severity Assessment: In addition to identifying potential sources of nitrosamine formation, the risk assessment involves evaluating the probability and severity of such formation. This means assessing how likely it is for nitrosamines to be produced and what the consequences would be in terms of patient safety and product quality.

Risk Mitigation Strategies: Once risks are identified and assessed, pharmaceutical manufacturers must develop and implement risk mitigation strategies. This could involve modifying processes, introducing quality control measures, or even changing suppliers for raw materials or solvents if they are found to be high-risk sources of nitrosamine precursors.

The GMP risk assessment in the context of nitrosamine formation is a comprehensive and proactive process. It aims to detect and address potential issues at every stage of drug development and manufacturing, ensuring that pharmaceutical products are safe, effective, and [14] compliant with regulatory standards.

Example: In the case of a hypothetical drug formulation, a rigorous risk assessment could entail a meticulous scrutiny of the synthesis pathway, the identification of potential sources of nitrosamine formation, and a comprehensive assessment of the probability and severity of their inadvertent formation.

.

4.2. Analytical Testing:

To Ensure Pharmaceutical Product Safety and Regulatory Compliance:

Pharmaceutical companies employ cutting-edge analytical techniques, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), to guarantee the safety and quality of their products. This involves two crucial aspects:

1. Detection and Quantification of Nitrosamine Impurities:

Nitrosamines are a class of compounds known for their potential carcinogenic properties and can inadvertently contaminate pharmaceutical products. Detecting and quantifying nitrosamines is a vital step in ensuring product safety. LC-MS/MS is the method of choice for [15] this task:

Detection: LC-MS/MS separates compounds within a sample based on their chemical properties and identifies them through mass spectrometry. Nitrosamines can be detected with high specificity and sensitivity, even in trace amounts, by recognizing their unique mass-to-charge ratios.

Quantification: LC-MS/MS also allows for the accurate quantification of nitrosamines in a sample by comparing the signal intensity of the nitrosamine peak to a known standard. This precision ensures that any potential health risks due to nitrosamine contamination can be meticulously assessed.

For example, consider a scenario where a pharmaceutical company employs LC-MS/MS to detect and quantify the presence of N-nitrosodimethylamine (NDMA) in a specific medication. NDMA is a known nitrosamine impurity with carcinogenic potential. Through LC-MS/MS, the company can not only confirm the presence of NDMA but also measure its concentration, ensuring it remains within permissible limits.

2. Compliance with Stringent Regulatory Limits:

Regulatory authorities, such as the FDA (Food and Drug Administration) [16] in the United States, establish rigorous limits for nitrosamine impurities in pharmaceutical products to safeguard public health. Pharmaceutical companies must adhere to these limits through comprehensive testing:

For instance, the FDA set stringent limits for nitrosamine impurities in medications, as demonstrated by the case of valsartan, a commonly used blood pressure medication. In 2018, several valsartan products were recalled due to elevated levels of NDMA. Manufacturers had to conduct extensive testing, including LC-MS/MS analysis, to determine the extent of contamination and implement corrective measures.

The emphasis on "unfailing compliance" underscores the critical need for continuous monitoring and rigorous adherence to these limits throughout the manufacturing process. It's not just about initial testing but also ongoing quality control to guarantee that products consistently meet these stringent regulatory requirements.

The utilization of advanced analytical methods like LC-MS/MS in pharmaceutical quality control is indispensable for detecting and quantifying potential harmful compounds, such as nitrosamines, and ensuring compliance with strict regulatory limits. This approach is vital for safeguarding public health and maintaining the integrity of pharmaceutical products.

Example: Regular and systematic testing of a pharmaceutical product for nitrosamine presence to guarantee that it aligns with the stipulated safety standards.

4.3. Process Optimization:

The statement "Pharmaceutical manufacturers can, and indeed should, proactively modify and optimize their production processes to significantly minimize the risk of nitrosamine formation" emphasizes the importance of pharmaceutical companies taking active measures to reduce the occurrence of nitrosamines in their drug manufacturing processes. Nitrosamines are potentially harmful compounds that can form in certain pharmaceutical products, and minimizing their presence is crucial for ensuring the safety of medicines.

The statement suggests several key actions that pharmaceutical manufacturers should consider taking:

Fine-tuning of reaction conditions: This involves making precise adjustments to the various factors that affect chemical reactions during drug synthesis. By carefully controlling parameters such as temperature, pressure, and reaction times, manufacturers can reduce the likelihood of nitrosamine formation.

Exploration of alternative solvents: Some solvents used in pharmaceutical manufacturing processes can contribute to nitrosamine formation. By researching and adopting alternative solvents that are less likely to produce nitrosamines, manufacturers can mitigate this risk.

Inclusion of purification steps: Purification steps are introduced to effectively remove potential nitrosamine precursors from the drug formulation. This can involve using specialized purification techniques and filters to eliminate impurities that may lead to nitrosamine formation.

The overall goal of these proactive modifications and optimizations is to create a safer and more reliable pharmaceutical product. Nitrosamines are considered potentially carcinogenic, so their presence in pharmaceuticals can pose serious health risks to patients. Therefore, it is not only in the best interest of patients but also a regulatory requirement for pharmaceutical manufacturers to take measures to minimize nitrosamine formation in their production processes. By doing so, they can enhance the quality and safety of their products and ensure compliance with relevant regulations and quality standards.

Example: If a particular solvent employed in a drug synthesis process is found to contain nitrosamine precursors, manufacturers may contemplate the utilization of alternative solvents that do not harbor such risks.

4.4. Risk Mitigation and Control Measures:

Pharmaceutical companies should institute and vigilantly uphold an array of control measures aimed at preventing nitrosamine contamination. Such measures might encompass the usage of premium quality raw materials, the rigorous monitoring of manufacturing processes, and the continuous oversight of suppliers to ensure unwavering compliance with the highest quality and safety standards.

Example: Pharmaceutical manufacturers may collaborate closely with their suppliers, necessitating that these suppliers provide meticulous documentation and certificates of analysis to ensure the quality and safety of raw materials.

4.5. Reporting and Regulatory Compliance:

In instances where nitrosamines are detected, timely and transparent reporting to regulatory authorities becomes of paramount importance. Adherence to regulatory guidelines, along with the proactive communication of the situation to healthcare professionals and the general public, are non-negotiable requisites for maintaining trust and ensuring patient safety.

Example: In cases where nitrosamines are detected in a pharmaceutical product, a manufacturer should act swiftly to apprise regulatory agencies, initiate recalls if deemed necessary, and provide clear, transparent communication to healthcare professionals and the public to maintain the highest standards of transparency and trustworthiness.

Conclusion:

The presence of nitrosamines in pharmaceutical products represents a substantial concern due to their potential carcinogenicity and the concomitant implications on regulatory compliance and patient safety. To effectively mitigate these risks, pharmaceutical manufacturers must faithfully implement a comprehensive array of control strategies, encompassing risk assessments, analytical testing, and process optimization. By meticulously adhering to these control measures, the pharmaceutical industry can continue to deliver pharmaceuticals that are both safe and efficacious, while simultaneously preserving the trust of patients and regulatory agencies. Continued research and development endeavors remain indispensable to deepen our understanding of nitrosamines and further refine control strategies within the pharmaceutical manufacturing process.

Acknowledgments :

The authors are thankful to the Management of GITAM University for providing thenecessary facilities to carry out this research work. [17,18]

Conflicts of interest:

There are no conflicts of interest among the authors who were done this present work.

Reference:

1. Karde, None H. V., et al. "A Comprehensive Review on Pharmaceutical Dosage Form." International Journal of Advanced Research in Science, Communication and Technology, 2023, https://doi.org/10.48175/ijarsct-8696.
2. Top General Range PCD Pharma Franchise Products company - Elkso Healthcare. https://elkosgroup.in/Top-General-Range-Pcd-Pharma-Franchise-Products-List.php
3. The TCPA and Its Implications for Credit Unions - TCPA Blog. https://tcpablog.com/tcpa-implications-credit-unions/
4. The Secret Ingredient to Lightning-Fast, Predictable Direct Mail - Lob. https://www.lob.com/events/the-secret-ingredient-to-lightning-fast-predictable-direct-mail
5. Aldehydic Fragrance Gallery | Konika Aromas. https://www.konikaaromas.com/aldehydic-fragrances/
6. . "Project Management Assistance Mission To Support The Contractual Management Of The Design-build Contract For The Construction Of The International Agency For Research On Cancer (Iarc) [Tender Documents : T455779020]." MENA Report, vol. , no. , 2020, p. .

7. Shanab, Ahmed A., et al. ""OxyElite Pro" Induced Fulminant Hepatotoxicity." 2018, https://doi.org/10.15226/2689-4432/2/1/00106.
8. Custom Packaging & Medical Device Packaging | Influence Packaging. https://influencepackaging.com/the-ultimate-guide-to-medical-device-packaging/
9. Pharmaceutical Microbiology. https://www.pharmamicroresources.com/2022/07/4-important-fda-regulations-for.html
10. Drozda, Katarzyna, and Michael Pacanowski. "Clinical Trial Designs to Support Clinical Utility of Pharmacogenomic Testing." Pharmacotherapy, 2017, https://doi.org/10.1002/phar.1971.
11. Petrun, Elizabeth L. "Organizational Response to Perceptual Risk: Managing Substantial Response to Unsubstantiated Events." 2013, https://core.ac.uk/download/232561898.pdf.
12. Bad Cybersecurity Habits: Break Them Now! - DMNews. https://www.dmnews.com/bad-cybersecurity-habits/
13. Risk Oversight: Caremark and COVID-19 Mandates | The Corporate Counsel. https://ccrcorp.com/corporate-counsel/articles/risk-oversight-caremark-and-covid-19-mandates/
14. Pharmaceutical Litigation Lawyers | STL Trial Lawyers. https://stltriallawyers.com/pharmaceutical-litigation-lawyer/
15. Midde, Narasimha, et al. "Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method." PLoS One, vol. 11, no. 2, 2016, p. e0149225.
16. Immunoassay: A Practical Guide - 1st Edition - Brian Law - Routledge B. https://www.routledge.com/Immunoassay-A-Practical-Guide/Law/p/book/9780748405602
17. Ravindranath, L. K., et al. "Synthesis and Characterization of Process Related Impurities of Tegaserod Maleate." Heterocyclic Communications, 2010, https://doi.org/10.1515/hc.2010.16.2-3.195.
18. Pluronic® P123-coated liposomal codelivery of paclitaxel and lapatinib enhances therapeutic potential via tumor cell targeting and overcoming multidrug resistance in triple-negative breast cancer cells. https://japsonline.com/abstract.php?article_id=3963&sts=2